• C Fuentes i Pumarola, R Casademont Mercader, M Colomer Plana, C Cordón Bueno, S Sabench Casellas, M Félez Vidal, and E Rodríguez Plazas.
• Departamento de Enfermería, Universidad de Girona, España. concepcio.fuentes@udg.es
• Enferm Intensiva. 2007 Jan 1; 18 (1): 25-35.

ObjectiveEstablish an action protocol for the maintenance of patency of the three lumen central venous catheters (CVC) when any of them are not used. The main variable of interest was evaluate it 24 hours.Material And MethodThis is a blind, randomized clinical trial. Phase 1: Comparison of efficacy, for maintenance of patency of the lumen at 24 hours and on discharge of the patient, of sodium heparin 500 IU (control 1), versus sodium heparin 100 IU (study 1). Phase 2: Once efficacy of sodium heparin 100 IU (control 2) was confirmed, we compared it with saline solution (SS) (study 2).Populationmultiple diseased patients admitted to eight critical care unit who were carriers of 3 lumen CVC without previous coagulation disorders.Analysisquantitative variables with mean (SD) analyzed with Student's t test and qualitative ones with -2.AnalysisSPSS 12.0 program.ResultsPhase 1: 128 catheters (control 1: 49, study 1: 79). Mean days of permanency with CVC: 5.4 (SD 6). At 24h, 100% of the CVC of both groups were patent. On discharge of the patient (n = 107) were not patent and 4.9% of the control group and 4.5% of the study group 1. Phase 2: 95 catheters (control 2: 38, study 2: 57) Mean days of permanency: 4.87 (SD 5). At 24h (n = 95), at 72 h (n = 66) and on discharge (n = 43), 100% of the CVC of both groups were patent. No significant difference was established in the two study phases between the groups studied with days of permanence, laboratory values and anticoagulant treatment.ConclusionsSS is as effective as 100 or 500 IU of heparin for maintenance of patency of CVC.

16 keywords...

hide…